Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 7/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334745 | 0.93 | NAAA (0.57) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL345276 | 0.93 | NAAA (0.57) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL345275 | 0.93 | NAAA (0.57) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL2872894 | 0.89 | NAAA (0.52) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL2872897 | 0.89 | NAAA (0.52) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL4521529 | 0.88 | NAAA (0.51) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL22800346 | 0.88 | NAAA (0.51) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL22800345 | 0.88 | NAAA (0.51) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL16594226 | 0.88 | NAAA (0.60) | NAAAFAAHFKBP1ANPC1TDP1 | |
| SCHEMBL16594224 | 0.88 | NAAA (0.60) | NAAAFAAHFKBP1ANPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | ARNOLD MACKLIN BRIAN (US) | 2004-05-20 | — | — | US | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | GRIN2A, GLUL, GRIK5 | NAAA 38/4885FAAH 160/4885FKBP1A 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.